Financing and Capital Raising - The Group raised gross proceeds of £13.4 million in February 2019 and £2.4 million in October 2019 through various offerings [771]. - A registered direct offering in May 2020 raised $3.0 million and £1.8 million in the UK, indicating ongoing capital-raising efforts [771]. - The Group anticipates requiring additional financing within the next 12 months to support development programs and operations, raising substantial doubt about its ability to continue as a going concern [771]. - The Group is evaluating near-term funding options, including fundraising and asset partnerships, as part of its strategic review [773]. - The Group's ability to continue as a going concern depends on obtaining additional capital or disposing of assets, with no assurance of timely or favorable terms [774]. Operational Risks - The impact of COVID-19 has introduced increased uncertainty over forecasts, potentially causing delays in operations [772]. - Liquidity risk arises from working capital management, with the aim to settle financial obligations as they become due [770]. Financial Risks - The total exposure to credit risk is equal to the total value of financial assets held at year-end, with a loss allowance recognized for expected credit losses [765]. - Foreign exchange risk is significant due to operations in Spain, with currency fluctuations impacting net assets when translated into British pounds sterling [768]. - The Group does not hedge its net investments in overseas operations due to the disproportionate cost relative to exposure [768].
Biodexa Pharmaceuticals PLC(BDRX) - 2019 Q4 - Annual Report